a clinical-stage biotechnology company discovering and developing cell and gene immunotherapies for solid and hematological malignancies, is presenting clinical data from a completed Phase 1 trial ...

is presenting clinical data from a completed Phase 1 trial evaluating a novel autologous HER2-targeted CAR-T therapy. The data presented today at the ASCO Gastrointestinal Cancers Symposium ...

may improve outcomes in patients with HER2-positive gastric or gastroesophageal junction (GEJ) cancer, according to research presented at the ASCO Gastrointestinal Cancers Symposium 2025.

Webcast on January 23 at 1:00 p.m. PT/4:00 p.m. ET will review updated data from trial evaluating CD47-blocker evorpacept in HER2-positive gastric cancer SOUTH SAN FRANCISCO ... at the 2025 American ...

LBA331: The EORTC-1203 GITC INNOVATION trial (NCT02205047) is evaluating the integration of trastuzumab (Herceptin), with or without pertuzumab (Perjeta), into perioperative chemotherapy for patients ...

First set of abstracts released include Signatera™ data from BESPOKE CRC, the largest prospective, observational, multicenter MRD study in the U.S. to date, along with the first read-outs in early ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

About 3,140 new cancers (mainly melanomas) of the eye and orbit (1,620 in men and 1,520 in women) About 490 deaths from cancers of the eye and orbit (270 in men and 220 in women) Primary eye cancers ...

Trastuzumab emtansine (T-DM1) demonstrates sustained improvement in invasive disease-free survival and reduced the risk for death in human epidermal growth factor receptor 2 (HER2)-positive breast ...